Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Cyclacel Pharmaceuticals ( (CYCC) ).
On July 16, 2025, Cyclacel Pharmaceuticals addressed recent stock price volatility, stating there were no material changes in its operations or financial condition that would explain the fluctuations observed on July 15, 2025. The company highlighted a recent amendment to an Exchange Agreement with FITTERS Diversified Berhad as the only significant public disclosure, indicating no adverse changes to its business strategy or prospects.
The most recent analyst rating on (CYCC) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Cyclacel Pharmaceuticals stock, see the CYCC Stock Forecast page.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology. Their pipeline includes plogosertib, a PLK1 inhibitor, aimed at treating both solid tumors and hematological malignancies.
Average Trading Volume: 1,276,867
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.24M
For an in-depth examination of CYCC stock, go to TipRanks’ Overview page.